Use of amifostine combined with ursolic acid in the preparation of a preparation for preventing and / or treating radiation-induced lung injury
The combined use of amifostine and ursolic acid overcomes the limitations of single-mechanism drugs in the prevention and treatment of radiation-induced lung injury in existing technologies, achieving multi-stage and multi-target protection against radiation-induced lung injury, significantly reducing lung tissue damage, and showing good prospects for clinical translation.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- XINXIANG MEDICAL UNIV
- Filing Date
- 2026-06-03
- Publication Date
- 2026-07-17
AI Technical Summary
There is a lack of highly effective, low-toxicity drugs that can intervene in multiple aspects of radiation-induced lung injury in the current technology. Amifostine has a short half-life and large side effects in clinical applications, while ursolic acid has poor water solubility and low bioavailability. Research on its use alone or in combination for radiation-induced lung injury is still not systematic.
Amifostine and ursolic acid can be used in combination to form single or independent formulations that cover multiple stages of radiation-induced lung injury through different mechanisms. Amifostine focuses on the early clearance of free radicals during radiotherapy, while ursolic acid continuously intervenes in the inflammatory response and fibrosis process. These formulations can be prepared for oral, injection, inhalation, or transdermal administration.
It significantly eliminates X-ray-induced reactive oxygen species, protects cells from radiation damage, reduces lung fibrosis scores, reduces systemic adverse reactions, overcomes the bioavailability deficiency of ursolic acid, and provides the advantages of multi-target and multi-stage comprehensive intervention.
Smart Images
Figure CN122398820A_ABST